• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent Esophageal Candidiasis Induced by Secukinumab: Discrepancy between Clinical Trials and Real-World Data.

作者信息

Seo Ji-In, Shin Min-Kyung, Jeong Ki-Heon

机构信息

Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea.

出版信息

Ann Dermatol. 2023 Apr;35(2):158-160. doi: 10.5021/ad.20.327.

DOI:10.5021/ad.20.327
PMID:37041712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10112366/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aca/10112366/28163b2d8c98/ad-35-158-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aca/10112366/ef301cc81438/ad-35-158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aca/10112366/28163b2d8c98/ad-35-158-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aca/10112366/ef301cc81438/ad-35-158-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aca/10112366/28163b2d8c98/ad-35-158-g002.jpg

相似文献

1
Recurrent Esophageal Candidiasis Induced by Secukinumab: Discrepancy between Clinical Trials and Real-World Data.司库奇尤单抗诱发的复发性食管念珠菌病：临床试验与真实世界数据之间的差异
Ann Dermatol. 2023 Apr;35(2):158-160. doi: 10.5021/ad.20.327.
2
Safety of secukinumab for the treatment of active ankylosing spondylitis.司库奇尤单抗治疗活动性强直性脊柱炎的安全性。
Expert Opin Drug Saf. 2021 Jun;20(6):627-634. doi: 10.1080/14740338.2021.1851363. Epub 2021 Jan 20.
3
Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab).白介素 17 抑制剂（司库奇尤单抗）靶向免疫治疗期间银屑病患者出现非典型口腔念珠菌病。
BMC Oral Health. 2021 Jun 8;21(1):292. doi: 10.1186/s12903-021-01653-6.
4
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.司库奇尤单抗在真实世界中治疗银屑病的有效性和安全性：按既往生物制剂治疗失败或报销情况分层的亚组分析
Ther Adv Chronic Dis. 2019 Apr 17;10:2040622319843756. doi: 10.1177/2040622319843756. eCollection 2019.
5
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.司库奇尤单抗治疗拉丁美洲中重度斑块状银屑病患者的有效性和安全性：PURE注册研究12个月数据。
Dermatol Ther (Heidelb). 2023 Jan;13(1):269-283. doi: 10.1007/s13555-022-00849-0. Epub 2022 Dec 10.
6
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.使用司库奇尤单抗治疗中重度银屑病（包括头皮和掌跖部银屑病）的真实世界数据：一项 104 周的临床研究。
Dermatol Ther. 2019 Sep;32(5):e13006. doi: 10.1111/dth.13006. Epub 2019 Jul 15.
7
Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety.泰国中重度银屑病患者使用司库奇尤单抗的真实世界经验：特征、疗效和安全性。
Dermatol Ther. 2022 Dec;35(12):e15958. doi: 10.1111/dth.15958. Epub 2022 Nov 16.
8
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).阿达木单抗、乌司奴单抗和司库奇尤单抗在银屑病患者中的药物留存率：一项来自英国皮肤科医师协会生物制剂与免疫调节剂登记处（BADBIR）的前瞻性队列研究。
Br J Dermatol. 2020 Aug;183(2):294-302. doi: 10.1111/bjd.18981. Epub 2020 Mar 30.
9
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study.司库奇尤单抗治疗掌跖银屑病：一项为期2年的多中心真实世界观察性研究。
Expert Opin Biol Ther. 2022 Apr;22(4):547-554. doi: 10.1080/14712598.2022.2029841. Epub 2022 Jan 20.
10
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.在真实环境中使用司库奇尤单抗治疗斑块状银屑病患者：西班牙的一项 52 周、多中心、回顾性研究。
J Dermatolog Treat. 2019 Aug;30(5):424-429. doi: 10.1080/09546634.2018.1528000. Epub 2018 Dec 3.

本文引用的文献

1
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.白细胞介素-17 抑制剂治疗银屑病和银屑病关节炎患者的念珠菌感染及其实际管理。
Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.
2
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies.白细胞介素-23/白细胞介素-17A功能障碍表型提示抗白细胞介素-17A疗法可能产生的临床效果。
J Invest Dermatol. 2015 Aug;135(8):1946-1953. doi: 10.1038/jid.2015.144. Epub 2015 Mar 24.
3
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
与生物制剂和非生物制剂银屑病全身治疗相关的严重不良事件风险：不符合与符合随机对照试验条件的患者
Arch Dermatol. 2012 Apr;148(4):463-70. doi: 10.1001/archdermatol.2011.2768.
4
The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal.关于临床试验数据反映药物长期安全性的错误认知：从依法利珠单抗撤市中吸取的教训
Arch Dermatol. 2009 Sep;145(9):1037-9. doi: 10.1001/archdermatol.2009.188.
5
Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review.发表于高影响力综合医学期刊的随机对照试验的纳入标准：一项系统抽样综述
JAMA. 2007 Mar 21;297(11):1233-40. doi: 10.1001/jama.297.11.1233.